Schonfeld Strategic Advisors’s CERo Therapeutics Warrants CEROW Stock Holding History

Schonfeld Strategic Advisors’s Portfolio CEROW Stock Details CEROW Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-15,000	Closed	-$217	–	2627
2025 Q1	$217	Hold	15,000	–	–	﹤0.01%	2163
2024 Q4	$124	Hold	15,000	–	–	﹤0.01%	1951
2024 Q3	$76	Hold	15,000	–	–	﹤0.01%	1988
2024 Q2	$301	Sell	15,000 -5,000	-25%	-$293	﹤0.01%	2093
2024 Q1	$1.36K	Sell	20,000 -13,373	-40%	-$813	﹤0.01%	1976
2023 Q4	$917	Hold	33,373	–	–	﹤0.01%	1772
2023 Q3	$2.39K	Sell	33,373 -2,627	-7%	-$188	﹤0.01%	1626
2023 Q2	$2.36K	Hold	36,000	–	–	﹤0.01%	1987
2023 Q1	$1.44K	Hold	36,000	–	–	﹤0.01%	1979
2022 Q4	$1.55K	Hold	36,000	–	–	﹤0.01%	2440
2022 Q3	$3K	Hold	36,000	–	–	﹤0.01%	2770
2022 Q2	$4K	Buy	+36,000	New	+$5.8K	﹤0.01%	2338

Other funds holding CEROW

Cantor Fitzgerald New York $6.78B AUM 28.97% 1-Year Est. Return

Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $69.7B AUM 40.86% 1-Year Est. Return

MMCAP International Grand Cayman, Cayman Islands $1.16B AUM 76.63% 1-Year Est. Return

SCM

Saba Capital Management New York $3.62B AUM 12.96% 1-Year Est. Return

CSD

Clear Street Derivatives New York $12.4M AUM 1.7% 1-Year Est. Return

Linden Advisors New York $17.9B AUM 1.72% 1-Year Est. Return

BOCH

Blue Owl Capital Holdings New York $372M AUM 78.25% 1-Year Est. Return

Clear Street New York $24.6B AUM 56.25% 1-Year Est. Return

QGA

Q Global Advisors Fort Worth, Texas $113M AUM 20.91% 1-Year Est. Return

CCM

Context Capital Management Lajolla, California $5.15B AUM 1.28% 1-Year Est. Return

Schonfeld Strategic Advisors's CEROW Position: Q2 2025 in Review

Schonfeld Strategic Advisors sold out of CERo Therapeutics Warrants (CEROW) in Q2 2025, closing a stake of 15,000 shares — an estimated $217 sold.

Schonfeld Strategic Advisors first reported a position in CEROW in Q2 2022 and held it in 12 quarters. The position peaked at $4K in Q2 2022. 23 funds tracked by Wall St. Rank hold CEROW as of Q2 2025.

Schonfeld Strategic Advisors reported no remaining CERo Therapeutics Warrants position as of Q2 2025 after selling out during the quarter.
Schonfeld Strategic Advisors sold 15,000 CERo Therapeutics Warrants shares in Q2 2025, an estimated $217.
Schonfeld Strategic Advisors first reported a position in CERo Therapeutics Warrants in Q2 2022 and held it in 12 quarters.
Schonfeld Strategic Advisors's CERo Therapeutics Warrants position peaked at $4K in Q2 2022.
23 funds tracked by Wall St. Rank held CERo Therapeutics Warrants as of Q2 2025.

Based on Schonfeld Strategic Advisors's 13F filing for Q2 2025, filed 14 Aug 2025.